Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × pasireotide × Gynecologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 13 Gastrointestinal 9 NET 7 Genitourinary 4 Thoracic 2 Lymphoid 2 Dermatologic 2 Breast 2 Sarcoma 1 Plasma cell 1 Other hematologic neoplasm 1 Myeloid 1 Head & Neck 1 Gynecologic 1 CNS 1

Conditions

Peritoneal Neoplasms 1

Interventions

Paclitaxel 480 Carboplatin 438 Cisplatin 280 Bevacizumab 206 pembrolizumab 188 Gemcitabine 122 Cyclophosphamide 110 olaparib 102 liposomal doxorubicin 99 Topotecan 99 Radiotherapy 91 Taxes 86 Docetaxel 79 Brachytherapy 77 Drug Therapy 70 Doxorubicin 70 niraparib 63 Nivolumab 61 Magnetic Resonance Spectroscopy 55 Specimen Handling 54 fludarabine 51 Biopsy 48 Hyperthermic Intraperitoneal Chemotherapy 43 Filgrastim 42 durvalumab 40 Letrozole 40 atezolizumab 36 Platinum 36 Oxaliplatin 36 Radiation 35

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04826432 2024-02-08

PASIREOCHIP

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Terminated

Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡